Menu
Not yet recruiting NCT07160894

Evaluation of Nucleotide-Binding Oligomerization Domain-Containing Protein (NOD) 1 and NOD 2

No phase Interventional Periodontal Diseases Inflammation

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Saliva and Serum sampling, Saliva and Serum sampling.
Who it may be relevant to
Registry conditions: Periodontal Diseases Inflammation. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Turkey (Türkiye)
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Evaluation of Nucleotide-Binding Oligomerization Domain-Containing Protein (NOD) 1 and NOD 2 in Different Periodontal Conditions

Overview

The host immune response to microorganisms is primarily recognized by pattern recognition receptors (PRRs), including toll-like receptors and nucleotide-binding oligomeric domain (NOD) receptors (NLRs). The aim of this study was to examine the relationship between periodontal disease and NOD in serum and saliva samples.

Detailed description

Healthy participants (n:25), gingivitis (n:25) patients and stage III, grade B periodontitis (n:25) patients enrolled for this study. Clinical periodontal parameters and salivary flow rate were noted. Serum and saliva samples were collected to measure NOD1, NOD2, IL-10 and IL-6 levels.

Interventions

  • Other Saliva and Serum sampling
    Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 5 mL of blood samples were collected by qualified staff from each participant.Saliva and serum were then stored at -80 °C until analysis.
  • Other Saliva and Serum sampling
    ELISA method will be used to measure IL-10 and IL-6 values in collected saliva and serum samples. For ELISA analysis, a commercial kit (Sunred Bio, Shanghai, China) pre-coated with human selected antibodies will be used.

Primary outcome measures

  • Pocket probing depth [Time frame: 6 months]
  • Clinical attachment level [Time frame: 6 months]
  • Bleeding on probing [Time frame: 6 months]
Secondary outcome measures (1)
  • Saliva and serum samples processing and analyses [Time frame: 1 month]

Eligibility criteria

Inclusion criteria

  • systemically healthy
  • clinical diagnosis of periodontal health
  • clinical diagnosis of periodontitis
  • clinical diagnosis of gingivitis

Exclusion criteria

  • • history of regular use of systemic antibiotics anti-inflammatory, or antioxidant drugs (previous 3 months)
  • nonsurgical periodontal treatment (previous 6 months)
  • surgical periodontal treatment (previous 12 months)
  • presence of<10 teeth
  • current medications affecting gingival health (calcium channel blockers, phenytoin, cyclosporine, and hormone replacement therapy)
  • diabetes
  • diagnosis of rheumatoid arthritis
  • pregnancy
  • lactating
  • smoking
  • excessive alcohol consumption.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Single group
Masking
Open label
Primary purpose
Prevention

Study locations

Turkey (Türkiye) · 1 center
  • Istanbul Medipol University, School of Dentistry — Istanbul

Identifiers

NCT: NCT07160894 · 672

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗